シンバイオ製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2022/01/17 | 1,075 | 1,081 | 1,035 | 1,035 | -41 | -3.8% | 589,500 |
2022/01/14 | 1,081 | 1,091 | 1,066 | 1,076 | -25 | -2.3% | 924,000 |
2022/01/13 | 1,107 | 1,126 | 1,091 | 1,101 | -13 | -1.2% | 654,600 |
2022/01/12 | 1,095 | 1,125 | 1,091 | 1,114 | +38 | +3.5% | 1,264,800 |
2022/01/11 | 1,036 | 1,087 | 1,032 | 1,076 | +35 | +3.4% | 1,184,300 |
2022/01/07 | 1,075 | 1,084 | 1,027 | 1,041 | -30 | -2.8% | 1,078,500 |
2022/01/06 | 1,075 | 1,104 | 1,068 | 1,071 | -33 | -3% | 1,100,100 |
2022/01/05 | 1,155 | 1,155 | 1,094 | 1,104 | -54 | -4.7% | 1,368,400 |
2022/01/04 | 1,150 | 1,166 | 1,125 | 1,158 | +13 | +1.1% | 926,400 |
2021/12/30 | 1,127 | 1,152 | 1,107 | 1,145 | +4 | +0.4% | 966,900 |
2021/12/29 | 1,087 | 1,147 | 1,085 | 1,141 | +52 | +4.8% | 1,365,600 |
2021/12/28 | 1,118 | 1,122 | 1,070 | 1,089 | -21 | -1.9% | 1,314,500 |
2021/12/27 | 1,141 | 1,145 | 1,106 | 1,110 | -33 | -2.9% | 1,238,300 |
2021/12/24 | 1,145 | 1,173 | 1,137 | 1,143 | +6 | +0.5% | 1,103,000 |
2021/12/23 | 1,152 | 1,155 | 1,123 | 1,137 | -4 | -0.4% | 773,200 |
2021/12/22 | 1,121 | 1,157 | 1,104 | 1,141 | +25 | +2.2% | 1,209,100 |
2021/12/21 | 1,134 | 1,137 | 1,090 | 1,116 | +15 | +1.4% | 1,191,000 |
2021/12/20 | 1,160 | 1,186 | 1,100 | 1,101 | -80 | -6.8% | 1,696,100 |
2021/12/17 | 1,180 | 1,205 | 1,164 | 1,181 | -19 | -1.6% | 1,248,500 |
2021/12/16 | 1,198 | 1,210 | 1,168 | 1,200 | +30 | +2.6% | 1,309,700 |
2021/12/15 | 1,134 | 1,189 | 1,133 | 1,170 | +22 | +1.9% | 1,150,000 |
2021/12/14 | 1,143 | 1,183 | 1,139 | 1,148 | -11 | -0.9% | 979,400 |
2021/12/13 | 1,190 | 1,194 | 1,138 | 1,159 | -21 | -1.8% | 1,434,400 |
2021/12/10 | 1,196 | 1,213 | 1,166 | 1,180 | -20 | -1.7% | 1,684,300 |
2021/12/09 | 1,261 | 1,285 | 1,194 | 1,200 | -91 | -7% | 3,136,400 |
2021/12/08 | 1,206 | 1,299 | 1,200 | 1,291 | +89 | +7.4% | 2,820,400 |
2021/12/07 | 1,197 | 1,227 | 1,170 | 1,202 | +61 | +5.3% | 2,181,100 |
2021/12/06 | 1,200 | 1,210 | 1,131 | 1,141 | -95 | -7.7% | 2,476,500 |
2021/12/03 | 1,190 | 1,273 | 1,171 | 1,236 | +60 | +5.1% | 3,976,300 |
2021/12/02 | 1,235 | 1,253 | 1,159 | 1,176 | -67 | -5.4% | 2,585,000 |
2021/12/01 | 1,320 | 1,340 | 1,187 | 1,243 | -61 | -4.7% | 3,230,000 |
2021/11/30 | 1,416 | 1,440 | 1,292 | 1,304 | -94 | -6.7% | 3,455,700 |
2021/11/29 | 1,403 | 1,467 | 1,380 | 1,398 | -79 | -5.3% | 3,607,700 |
2021/11/26 | 1,585 | 1,608 | 1,445 | 1,477 | -87 | -5.6% | 3,319,100 |
2021/11/25 | 1,758 | 1,758 | 1,460 | 1,564 | -193 | -11% | 6,600,600 |
2021/11/24 | 1,782 | 1,852 | 1,755 | 1,757 | -24 | -1.3% | 5,375,200 |
2021/11/22 | 1,750 | 1,888 | 1,718 | 1,781 | +7 | +0.4% | 8,743,700 |
2021/11/19 | 1,789 | 1,813 | 1,724 | 1,774 | -26 | -1.4% | 4,795,700 |
2021/11/18 | 1,791 | 1,867 | 1,701 | 1,800 | +99 | +5.8% | 14,659,900 |
2021/11/17 | 1,429 | 1,701 | 1,418 | 1,701 | +300 | +21.4% | 12,563,100 |
2021/11/16 | 1,490 | 1,610 | 1,362 | 1,401 | +54 | +4% | 15,079,300 |
2021/11/15 | 1,347 | 1,347 | 1,347 | 1,347 | +300 | +28.7% | 317,600 |
2021/11/12 | 1,047 | 1,047 | 1,047 | 1,047 | +150 | +16.7% | 163,700 |
2021/11/11 | 931 | 934 | 890 | 897 | -25 | -2.7% | 1,782,200 |
2021/11/10 | 930 | 952 | 913 | 922 | -8 | -0.9% | 1,015,400 |
2021/11/09 | 943 | 963 | 925 | 930 | -15 | -1.6% | 1,320,200 |
2021/11/08 | 992 | 1,002 | 934 | 945 | -54 | -5.4% | 2,122,400 |
2021/11/05 | 1,039 | 1,039 | 990 | 999 | -40 | -3.8% | 1,545,200 |
2021/11/04 | 1,039 | 1,065 | 1,025 | 1,039 | +14 | +1.4% | 807,500 |
2021/11/02 | 1,038 | 1,051 | 1,020 | 1,025 | ±0 | ±0% | 731,700 |
851~
900
件表示中 / 3355件
類似銘柄と比較する
現在ご覧いただいている「シンバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
シンバイオ | 17,200円 | -42.9% | - | 0.00% | - | 2.16倍 |
|
導入で新薬開発・製品化。抗がん剤「トレアキシン」国内販売。抗ウイルス薬BCVの開発に注力 |
仁 丹 | 212,500円 | +0.3% | +9.2% | 3.06% | 12.07倍 | 0.72倍 |
|
代名詞の仁丹から整腸作用軸に健康サプリ、医薬品へ展開。シームレスカプセル技術に特長 |
ソレイジア | 3,900円 | +311.4% | - | 0.00% | - | 7.49倍 |
|
がん柱の創薬ベンチャー。候補品導入後に開発進め権利再導出、製品販売を行うビジネスモデル |
DELTA-P | 75,100円 | - | - | 0.00% | - | 29.84倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
ケイファーマ | 70,100円 | - | - | 0.00% | - | 3.60倍 |
|
慶応大学発ベンチャー。iPS細胞による再生医療と創薬の2本柱。中枢神経系が得意領域 |
市場注目の銘柄
チャート関連のコラム